Antidepressant in animal models of depression and study of cognitive property

Swapnali Suresh Mankar; Satish Premsingh Turan; Swapnil Suresh Mankar; Pradip Ashruji Shelke

doi:10.30574/gscbps.2019.7.3.0069

Authors

Swapnali Suresh Mankar Department of Quality Assurance, Agnihotri College of Pharmacy, Wardha, Pin 442001 Maharashtra India.
Satish Premsingh Turan PDM School of Pharmacy, Karsindhu, Safidon, Jind 126112 Haryana, India.
Swapnil Suresh Mankar Jamanlal Goyanka Dental College and Hospital, Akola 444002 Maharashtra India.
Pradip Ashruji Shelke Department of Quality Assurance, Agnihotri College of Pharmacy, Wardha, Pin 442001 Maharashtra India.

DOI:

https://doi.org/10.30574/gscbps.2019.7.3.0069

Keywords:

Bacopa monnieri Linn, Forced swim test, Tail suspension test, GABAergic activity

Abstract

Depression characterized by significant depression of mood and impairment of function .In whole study evaluate the antidepressant activity of ethanolic extract of Bacopa monnieri Linn, to assess the pharmacodynamic interaction of drug with standard nootropic antidepressant, determine effect of drug alone and in combination with standard anti-depressant in brain on amino acid neurotransmitter and acetylcholine esterase activity. Despair Swim test and tail suspension test study of interaction of ethanolic extract Bacopa monnieri with standard antidepressant drug extract used in FST and TST studied. Final perception was GABAmimetic Bacopa monneri decrease the immobility in forced swim test found that GABAergic activity lower in depressed state than normal brain. The control group in both FST and TST. GABA level found decrease than basal values. From experimental evidence it may conclude that ethanolic extract of Bacopa monnieri Linn possesses significant antidepressant activity.

Metrics

Metrics Loading ...

References

Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C and Smoker J. (2002). Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology (Wollongong), 27 (2), 279–81.

Stough C, Lloyd J, Clarke J, Downey L, Hutchison C, Rodgers T and Nathan P. (2001). The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl), 156 (4), 481–4.

Mukundh N, Balasubramanian, Muralidharan P and Balamurugan G. (2012). The transcription factor network associated with Amino acid response in mammalian cell Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL, 4(4), 310-313.

Gohil KJ and Patel JA. (2010). A review on Bacopa monnieri current research & future prospects. International Journal of Green Pharmacy J sterol, 215-219.

Anderson IM. (2001). Meta-analytical studies on new antidepressants. British Medical Bulletin, 57,161-178.

Harrison Tr, Kasper DL, Brauvolt E, Fax AS. (2005) Harrisons Principles of Internal Medicine, 16th edn, Mcgraw Hill Publications, New York, 2549-2554.

Baldessarini RJ and Tohen M. (1988). Is there a long-term protective effect of mood-altering agents in unipolar depressive disorder? In, Psychopharmacology: Current Trends. (Casey, D.E., and Christensen, A.V, eds.) Springer-Verlag, Berlin: 130-139.

Blier P, de Montigny C and Chaput Y. (1990). A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J. Clin. Psychiatry, 51(suppl), 14-20.

Bodkin JA, Zornberg GL, Lukas SE and Cole JO. (1995). Buprenorphine treatment of refractory depression. Journal of Clinical Psychopharmacology, 15 (1), 49–57.

Schreiber S, Bleich A and Pick CG. (2002). Venlafaxine and mirtazapine: different mechanism of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? J Molecular Neuroscience, 13 (1-2), 143-9.

Kasa K. (1982). Cerebrospinal fluid gamma_amino butyric acid and homovanillin acid in depressive disorders. Biolpsychiatry, 8, 877-83.

Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A and Mason GF. (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular psychiatry, 7(S1), S71.

Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ and Di Paolo T. (1999). Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABAA/benzodiazepine receptor complex and GABA content. Neurochemistry international, 35(1), 81-91.

Rada P, Colasante C, Skirzewski M, Hernandez L and Hoebel B. (2006). Behavioral depression in the swim test causes a biphasic, long-lasting change in accumbens acetylcholine release, with partial compensation by acetylcholinesterase and muscarinic-1 receptors. Neuroscience, 141(1), 67-76.

Giacobini E. (2004). Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacological research, 50(4), 433-440.